Tags

Type your tag names separated by a space and hit enter

Treatment of obesity: an update on anti-obesity medications.
Obes Rev. 2003 Feb; 4(1):25-42.OR

Abstract

The information presented in this article provides an overview of physiological agents, therapeutics in current use, and medications that have been extensively used in the past but are no longer available, or are not classically considered as anti-obesity drugs. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral action energetic homeostasis (nutrients, monoamines and peptides), and on beta-phenethylamine pharmacological-derivative agents (fenfluramine, dexfenfluramine, phentermine, diethylpropion, fenproporex and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrine, phenylpropanolamine), a phenylpropanolamine oxy-tri-fluor-phenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials longer than 10 weeks in duration is also presented for medications used in the management of obesity.

Authors+Show Affiliations

Obesity and Metabolic Diseases Group, Endocrinology and Metabology Service, Clinics Hospital, University of São Paulo Medical School, São Paulo, Brazil. halpern@netpoint.com.brNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12608525

Citation

Halpern, A, and M C. Mancini. "Treatment of Obesity: an Update On Anti-obesity Medications." Obesity Reviews : an Official Journal of the International Association for the Study of Obesity, vol. 4, no. 1, 2003, pp. 25-42.
Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obes Rev. 2003;4(1):25-42.
Halpern, A., & Mancini, M. C. (2003). Treatment of obesity: an update on anti-obesity medications. Obesity Reviews : an Official Journal of the International Association for the Study of Obesity, 4(1), 25-42.
Halpern A, Mancini MC. Treatment of Obesity: an Update On Anti-obesity Medications. Obes Rev. 2003;4(1):25-42. PubMed PMID: 12608525.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of obesity: an update on anti-obesity medications. AU - Halpern,A, AU - Mancini,M C, PY - 2003/3/1/pubmed PY - 2003/6/20/medline PY - 2003/3/1/entrez SP - 25 EP - 42 JF - Obesity reviews : an official journal of the International Association for the Study of Obesity JO - Obes Rev VL - 4 IS - 1 N2 - The information presented in this article provides an overview of physiological agents, therapeutics in current use, and medications that have been extensively used in the past but are no longer available, or are not classically considered as anti-obesity drugs. The authors present an extensive review on the criteria for anti-obesity management efficacy, on physiological mechanisms that regulate central and/or peripheral action energetic homeostasis (nutrients, monoamines and peptides), and on beta-phenethylamine pharmacological-derivative agents (fenfluramine, dexfenfluramine, phentermine, diethylpropion, fenproporex and sibutramine), tricyclic derivatives (mazindol), phenylpropanolamine derivatives (ephedrine, phenylpropanolamine), a phenylpropanolamine oxy-tri-fluor-phenyl derivative (fluoxetine), a naftilamine derivative (sertraline) and a lipstatine derivative (orlistat). An analysis of all clinical trials longer than 10 weeks in duration is also presented for medications used in the management of obesity. SN - 1467-7881 UR - https://www.unboundmedicine.com/medline/citation/12608525/Treatment_of_obesity:_an_update_on_anti_obesity_medications_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=1467-7881&date=2003&volume=4&issue=1&spage=25 DB - PRIME DP - Unbound Medicine ER -